Search results for "EJECTION FRACTION"

showing 10 items of 378 documents

Burden of Recurrent Hospitalizations Following an Admission for Acute Heart Failure: Preserved Versus Reduced Ejection Fraction.

2017

Abstract Introduction and objectives Heart failure with preserved ejection fraction and reduced ejection fraction share a high mortality risk. However, differences in the rehospitalization burden over time between these 2 entities remains unclear. Methods We prospectively included 2013 consecutive patients discharged for acute heart failure. Of these, 1082 (53.7%) had heart failure with preserved ejection fraction and 931 (46.2%) had heart failure with reduced ejection fraction. Cox and negative binomial regression methods were used to evaluate the risks of death and repeat hospitalizations, respectively. Results At a median follow-up of 2.36 years (interquartile range: 0.96-4.65), 1018 pat…

Malemedicine.medical_specialtyanimal structures030204 cardiovascular system & hematologyPatient Readmission03 medical and health sciencesVentricular Dysfunction Left0302 clinical medicineCost of IllnessInterquartile rangeRecurrenceInternal medicinemedicineHumans030212 general & internal medicineAgedHeart FailureEjection fractionbusiness.industryStroke VolumeGeneral Medicinemedicine.diseaseConfidence intervalHospitalizationHeart failureAcute DiseaseCardiologyFemalebusinessHeart failure with preserved ejection fractionRevista espanola de cardiologia (English ed.)
researchProduct

Percutaneous coronary intervention of chronic total occlusions in patients with low left ventricular ejection fraction

2017

Abstract Objectives The study sought to assess the outcome of percutaneous coronary intervention (PCI) of chronic total occlusions (CTOs) in patients with low left ventricular ejection fraction (LVEF) (≤35%). Background Data regarding the outcome of PCI in patients with low LVEF affected by CTO are scarcely reported. Methods The authors performed a prospective longitudinal multicenter study including consecutive patients undergoing elective PCI of CTOs. Patients were subdivided into 3 groups: group 1 (LVEF ≥50%), group 2 (LVEF 35% to 50%), and group 3 (LVEF ≤35%). Results A total of 839 patients (mean 64.6 ± 10.5 years of age, 87.7% men) underwent CTO PCI attempts. Baseline LVEF ≤35% was pr…

Malemedicine.medical_specialtyanimal structuresTime Factorsmedicine.medical_treatment610 Medicine & healthKaplan-Meier Estimate030204 cardiovascular system & hematologyCoronary AngiographyDisease-Free SurvivalVentricular Function Left2705 Cardiology and Cardiovascular Medicinechronic total occlusion; ischemic LV dysfunction; left ventricular ejection fraction; PCI; Cardiology and Cardiovascular Medicinechronic total occlusionischemic LV dysfunctionleft ventricular ejection fractionPCI03 medical and health sciences0302 clinical medicinePercutaneous Coronary InterventionRisk FactorsInternal medicinemedicineHumansIn patientcardiovascular diseases030212 general & internal medicineLongitudinal StudiesProspective Studieschronic total occlusionAgedProportional Hazards ModelsEjection fractionbusiness.industryPercutaneous coronary interventionleft ventricular ejection fractionPCIStroke VolumeRecovery of FunctionMiddle AgedSurgeryEuropeTreatment OutcomeCoronary OcclusionConventional PCIChronic DiseaseCardiology10209 Clinic for CardiologyFemalebusinessCardiology and Cardiovascular Medicineischemic LV dysfunction
researchProduct

Comparison between CA125 and NT-proBNP for evaluating congestion in acute heart failure

2020

Abstract Background Carbohydrate antigen 125 (CA125) and B-type natriuretic peptides are surrogate markers of congestion in patients with acute heart failure (AHF). The aim of the study was to assess the association between CA125 and NT-proBNP and congestion parameters in patients with AHF. Methods and results Prospective multicentre observational study that included 191 patients hospitalised for AHF. We recorded the presence of pleural effusion, peripheral oedema and inferior vena cava (IVC) diameter during the first 24–48 h after admission and evaluated their independent association with CA125 concentrations and the amino-terminal fraction of pro-B-type natriuretic peptide (NT-proBNP). Th…

Malemedicine.medical_specialtyendocrine system diseasesmedicine.drug_classPleural effusionPeripheral edemaInferior vena cavaVentricular Function LeftInternal medicineNatriuretic Peptide BrainmedicineNatriuretic peptideHumansIn patientProspective StudiesAgedAged 80 and overHeart FailureEjection fractionbusiness.industryStroke VolumeMiddle AgedPrognosismedicine.diseasePeptide Fragmentsmedicine.veinHeart failureCardiologySerum ca125Femalemedicine.symptombusinessBiomarkersMedicina Clínica (English Edition)
researchProduct

Normal-sodium diet compared with low-sodium diet in compensated congestive heart failure: is sodium an old enemy or a new friend?

2007

The aim of the present study was to evaluate the effects of a normal-sodium (120 mmol sodium) diet compared with a low-sodium diet (80 mmol sodium) on readmissions for CHF (congestive heart failure) during 180 days of follow-up in compensated patients with CHF. A total of 232 compensated CHF patients (88 female and 144 male; New York Heart Association class II–IV; 55–83 years of age, ejection fraction <35% and serum creatinine <2 mg/dl) were randomized into two groups: group 1 contained 118 patients (45 females and 73 males) receiving a normal-sodium diet plus oral furosemide [250–500 mg, b.i.d. (twice a day)]; and group 2 contained 114 patients (43 females and 71 males) recei…

Malemedicine.medical_specialtyfood.dietLow sodium dietPlasma renin activityGastroenterologyPatient Readmissionchemistry.chemical_compoundfoodFurosemideInternal medicineNatriuretic Peptide BrainReninmedicineHumansDiureticsAldosteroneAgedAged 80 and overHeart FailureEjection fractionAldosteronebusiness.industryFurosemideSodium DietaryGeneral MedicineDiet Sodium-RestrictedMiddle Agedmedicine.diseaseBrain natriuretic peptideCombined Modality TherapySurvival AnalysisEndocrinologyTreatment OutcomechemistryHeart failureFemalebusinessmedicine.drugLow sodiumFollow-Up StudiesClinical science (London, England : 1979)
researchProduct

Role of PCSK9 in the course of ejection fraction change after ST-segment elevation myocardial infarction: a pilot study

2020

Altres ajuts: Conselleria d'Educació, Investigació, Cultura i Esport GV/2018/116 Proprotein convertase subtilisin/kexin type 9 (PCSK9) has emerged as a therapeutic target for reducing plasma low-density lipoprotein cholesterol. Beyond lipid control, recent findings suggest a deleterious effect of this protein in the pathogenesis of postmyocardial infarction left ventricle remodelling and heart failure-related complications. The aim of this study was to assess the relationship between circulating PCSK9 and 6 month cardiac magnetic resonance imaging-derived left ventricular ejection fraction (LVEF) after a first ST-segment elevation myocardial infarction (STEMI). We prospectively evaluated 40…

Malemedicine.medical_specialtylcsh:Diseases of the circulatory (Cardiovascular) systemLeft ventricular ejection fractionCardiac magnetic resonancemedicine.medical_treatmentMyocardial InfarctionInfarctionAngiotensin-Converting Enzyme InhibitorsPilot Projects030204 cardiovascular system & hematologyVentricular Function LeftPCSK9Angiotensin Receptor Antagonists03 medical and health sciences0302 clinical medicineCardiac magnetic resonance imagingOriginal Research ArticlesInternal medicinemedicineST‐segment elevation myocardial infarctionHumansST segmentOriginal Research Article030212 general & internal medicineMyocardial infarctioncardiovascular diseasesAgedKillip classEjection fractionmedicine.diagnostic_testbusiness.industryPercutaneous coronary interventionStroke VolumeMiddle Agedmedicine.diseaseST-segment elevation myocardial infarctionlcsh:RC666-701Heart failureCardiologyST Elevation Myocardial InfarctionProprotein Convertase 9Cardiology and Cardiovascular Medicinebusiness
researchProduct

Analysis of left ventricular volumes and function: a multicenter comparison of cardiac magnetic resonance imaging, cine ventriculography, and unenhan…

2013

Background: Contrast echocardiography improves accuracy and reduces interreader variability on left ventricular (LV)functional analyses inthe settingof two-dimensional (2D) echocardiography. Theneedfor contrast imaging using three-dimensional (3D) echocardiography is less defined. The aim of this multicenter study was to define the accuracy and interreader agreement of unenhanced and contrast-enhanced 2D and 3D echocardiography for the assessment of LV volumes and ejection fraction (EF). Methods: A multicenter, open-label study was conducted including 63 patients, using intrasubject comparisons to assess the agreement of unenhanced and contrast-enhanced 2D and 3D echocardiography as well as…

Malemedicine.medical_specialtymedia_common.quotation_subjectEchocardiography Three-DimensionalSulfur HexafluorideContrast MediaMagnetic Resonance Imaging CineSensitivity and SpecificityVentricular Dysfunction LeftCardiac magnetic resonance imagingInternal medicinemedicineContrast (vision)HumansRadiology Nuclear Medicine and imagingSingle-Blind MethodRadionuclide VentriculographyPhospholipidsmedia_commonObserver VariationEjection fractionmedicine.diagnostic_testbusiness.industryReproducibility of ResultsThree dimensional echocardiographyStroke VolumeOrgan SizeConfidence intervalEuropeContrast echocardiographyCardiologyFemaleCardiology and Cardiovascular MedicinebusinessCardiac magnetic resonanceNuclear medicine3d echocardiographyJournal of the American Society of Echocardiography : official publication of the American Society of Echocardiography
researchProduct

Bio-profiling and bio-prognostication of chronic heart failure with mid-range ejection fraction.

2018

Abstract Background Recent ESC guidelines on heart failure (HF) have introduced a new phenotype based on left ventricular ejection fraction (LVEF), called the mid-range (HFmrEF). This phenotype falls between the classical reduced (HFrEF) and preserved (HFpEF) HF phenotypes. We aimed to characterize the HFmrEF biomarker profile and outcomes. Methods 1069 consecutive ambulatory patients were included in the study (age 66.2 ± 12.8 years); 800 with HFrEF (74.8%), 134 with HFmrEF (12.5%), and 135 with HFpEF (12.5%). We measured serum concentrations of N-terminal pro-brain natriuretic peptide (NT-proBNP), high-sensitivity troponin T (hs-TnT), soluble suppression of tumorigenicity (ST2), galectin-…

Malemedicine.medical_specialtymedicine.drug_classGalectin 3030204 cardiovascular system & hematology03 medical and health sciences0302 clinical medicineTroponin TInternal medicineNatriuretic Peptide BrainNatriuretic peptidemedicineHumans030212 general & internal medicineSoluble transferrin receptorAgedAged 80 and overHeart FailureEjection fractionbiologyTroponin Tbusiness.industryHazard ratioStroke VolumeStroke volumeMiddle Agedmedicine.diseasePrognosisPeptide FragmentsDeathHeart failureChronic Diseasebiology.proteinCardiologyBiomarker (medicine)FemaleCardiology and Cardiovascular MedicinebusinessBiomarkersFollow-Up StudiesInternational journal of cardiology
researchProduct

Inflammation in right ventricular dysfunction due to thromboembolic pulmonary hypertension

2009

Activation of the immune system is well established in patients with chronic heart failure (CHF) and impaired left ventricular function. High levels of pro-inflammatory cytokines are associated with a poor prognosis. Chronic thromboembolic pulmonary hypertension (CTEPH) frequently leads to impaired right ventricular function. It is not known whether such patients display chronic immune activation as well.We studied 49 patients with CTEPH (50±2 years, right ventricular ejection fraction [RVEF] 29±2%, left ventricular ejection fraction [LVEF] 51±3%, mean±SEM) and compared their results with 17 patients with CHF (71±2 years, LVEF 23±1%) and 34 age-matched control subjects (age 57±2 years). We …

Malemedicine.medical_specialtymedicine.drug_classHypertension PulmonaryVentricular Dysfunction RightInflammationImmune systemInternal medicinemedicineNatriuretic peptideHumanscardiovascular diseasesReceptorInflammationEjection fractionbusiness.industryMiddle Agedmedicine.diseaseRight ventricular dysfunctionHeart failurecardiovascular systemCardiologyFemaleTumor necrosis factor alphamedicine.symptomPulmonary EmbolismCardiology and Cardiovascular MedicinebusinessInternational Journal of Cardiology
researchProduct

Effects of high-dose furosemide and small-volume hypertonic saline solution infusion in comparison with a high dose of furosemide as bolus in refract…

2003

Background Diuretics have been accepted as first-line treatment in refractory congestive heart failure (CHF), but a lack of response to them is a frequent event. A randomized, single-blind study was performed to evaluate the effects of the combination of high-dose furosemide and small-volume hypertonic saline solution (HSS) infusion in the treatment of refractory New York Heart Association (NYHA) class IV CHF and a normosodic diet during follow-up. Materials and Methods One hundred seven patients (39 women and 68 men, age range 65-90 years) with refractory CHF (NYHA class IV) of different etiologies, who were unresponsive to high oral doses of furosemide, angiotensin-converting enzyme inhib…

Malemedicine.medical_specialtymedicine.medical_treatmentAdministration OralDrug Administration ScheduleBolus (medicine)FurosemideHeart rateMedicineHumansSingle-Blind MethodDiureticsInfusions IntravenousBlood urea nitrogenAgedAged 80 and overHeart FailureSaline Solution HypertonicEjection fractionDose-Response Relationship Drugbusiness.industryFurosemideSodium Dietarymedicine.diseaseSurvival AnalysisSurgeryTreatment OutcomeHeart failureAnesthesiaQuality of LifeFemaleDiureticCardiology and Cardiovascular MedicinebusinessHyponatremiamedicine.drugFollow-Up StudiesAmerican heart journal
researchProduct

Echocardiographic and lung ultrasound characteristics in ambulatory patients with dyspnea or prior heart failure.

2013

Purpose Lung ultrasound (LUS) represents a novel, noninvasive method in the assessment of extravascular lung water. We investigated the utility of LUS in ambulatory subjects with dyspnea or prior heart failure (HF). Methods We studied 81 ambulatory subjects with HF history or dyspnea who underwent transthoracic echocardiography (TTE) with LUS of 8 zones. Subjects with heart transplantation or pulmonary conditions known to interfere with LUS were excluded. A reviewer blinded to the clinical data performed echocardiographic measurements and quantified B-lines (reverberation artifacts arising from the pleural line). Results Of 81 subjects, 74 (91%) (median age 66 years, 39% men, median left ve…

Malemedicine.medical_specialtymedicine.medical_treatmentBlood PressureRisk AssessmentSensitivity and SpecificityNuclear Medicine and ImagingInternal medicinemedicine.arterymedicineAmbulatory CareHumansRadiology Nuclear Medicine and imagingSingle-Blind MethodLungDyspnea; Echocardiography; Heart failure; Lung ultrasound; Aged; Ambulatory Care; Blood Pressure; Dyspnea; Echocardiography; Extravascular Lung Water; Female; Heart Failure; Humans; Lung; Male; Middle Aged; Prognosis; Reproducibility of Results; Risk Assessment; Sensitivity and Specificity; Single-Blind Method; Stroke Volume; Cardiology and Cardiovascular Medicine; Radiology Nuclear Medicine and ImagingAgedHeart transplantationHeart FailureLung ultrasoundEjection fractionbusiness.industryReproducibility of ResultsStroke VolumeStroke volumeMiddle Agedmedicine.diseasePrognosisBlood pressureDyspneaEchocardiographyHeart failureAmbulatoryPulmonary arteryExtravascular Lung WaterCardiologyVentricular pressureFemaleRadiologyCardiology and Cardiovascular MedicinebusinessEchocardiography (Mount Kisco, N.Y.)
researchProduct